Skip to content Skip to footer

Medical cannabis approvals show triple-digit annual growth in Australia

Medical cannabis approvals show triple-digit annual growth in Australia
Share this story

The Australian medical cannabis scheme has experienced triple-digit annual growth since cannabis was rescheduled for human therapeutic purposes in 2016.

Medical cannabis in Australia is an unlicensed product, not included in the Australian Register of Therapeutic Goods (ARTG). For this reason, doctors must consider treatment options included in the ARTG before applying to access an unapproved medical cannabis product. Advertisement of said products to the general public is not allowed, which has recently caused concerns within the Therapeutic Goods Administration (TGA).

Medical cannabis authorisations in Australia

Australian medical cannabis patients get access mainly through two different pathways:

  1. Authorised Prescriber scheme (AP): 89 doctors are currently registered to prescribe medical cannabis. Over 1,400 medical practitioners have prescribed medical cannabis products to date (note: this includes both AP and SAS B schemes).
  2. Special Access Scheme Category B (SAS B): More than 90% of medicinal cannabis applications are processed online. SAS B decisions for medicinal cannabis are, on average, made within 30 hours of submission. Less than 5% of SAS B applications are not accepted immediately but require further information to be provided from the prescriber.

Supply of medical cannabis products is increasing both through international imports and domestic production. As of December 2019, there were 87 licences to cultivate, produce and/or manufacture medicinal cannabis in Australia, which are collectively authorised to produce in excess of 35,000 kg of dried flower annually.

The rise in supply has brought a decrease in prices which has helped in terms of patient affordability, and also an increase in the number of formats available to patients, with over 130 individual products being prescribed at least once. This sets apart the Australian model from other pharmaceutically-controlled systems in place in Europe, where the number of products and formats available is much more restrictive.

Attitudes to regulation of medical cannabis in Australia

The results of a recent cross-sectional survey on medical users during the last 12 months found affordability a concern for a majority of users, with over 70% stating that the government should reimburse medical cannabis purchases. Nevertheless, the bureaucratic hurdles imposed by the Australian access schemes (AP and SAS B) seem to be of higher concern to patients, with almost 90% declaring that the system was difficult to navigate.

 

Recent posts
January 31, 2024
New Reforms Set to Send Israeli Medical Cannabis Patient Numbers Soaring – Industry Growth to Follow
January 31, 2024
LAUNCHING TODAY | The Israeli Cannabis Report
January 23, 2024
LAUNCHING TODAY | Oceania Regulatory Report
December 14, 2023
LAUNCHING TODAY | The Global Cannabis Report: 4th Edition

Catch up on our newest articles that you might have missed

israel cannabis reform
January 31, 2024
New Reforms Set to Send Israeli Medical Cannabis Patient Numbers Soaring – Industry Growth to Follow
The number of Israeli patients using medical cannabis is set to soar by 2027, as imminent reforms will make it...
Israel cannabis
January 31, 2024
LAUNCHING TODAY | The Israeli Cannabis Report
Prohibition Partners are proud to announce the publication of The Israeli Cannabis Report.  This report delves into the intricate journey...
WEB_slider-Oceania-report_2
January 23, 2024
LAUNCHING TODAY | Oceania Regulatory Report
Prohibition Partners are proud to announce the publication of the Oceania Regulatory Report today. This report provides a current regulatory...
luke-stackpoole-5Qqkjn4PFPA-unsplash
December 14, 2023
LAUNCHING TODAY | The Global Cannabis Report: 4th Edition
Prohibition Partners are proud to announce the publication of The Global Cannabis Report: 4th Edition. The legal cannabis industry in...